Last update 20 Nov 2026

Cytarabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-beta-D-Arabinofuranosylcytosine, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone, AC
+ [35]
Action
inhibitors
Mechanism
DNA-directed DNA polymerase inhibitors, DNA synthesis inhibitors
Drug Highest PhaseApproved
RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H13N3O5
InChIKeyUHDGCWIWMRVCDJ-CCXZUQQUSA-N
CAS Registry147-94-4

External Link

KEGGWikiATCDrug Bank
D00168Cytarabine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Meningeal Leukemia
Australia
12 Jun 2026
Non-Hodgkin Lymphoma
Australia
12 Jun 2026
Blast Phase Chronic Granulocytic Leukemia
Brazil
08 Jan 2007
Lymphoma
Japan
11 Nov 2002
Meningeal Carcinomatosis
European Union
11 Jul 2001
Meningeal Carcinomatosis
Iceland
11 Jul 2001
Meningeal Carcinomatosis
Liechtenstein
11 Jul 2001
Meningeal Carcinomatosis
Norway
11 Jul 2001
Acute Myeloid Leukemia
Japan
18 Jan 2000
Bladder Cancer
Japan
15 Feb 1984
Bile Duct Neoplasms
Japan
24 Apr 1973
Breast Cancer
Japan
24 Apr 1973
Colonic Cancer
Japan
24 Apr 1973
Gallbladder Neoplasms
Japan
24 Apr 1973
Liver Cancer
Japan
24 Apr 1973
Lung Cancer
Japan
24 Apr 1973
Ovarian Cancer
Japan
24 Apr 1973
Pancreatic Cancer
Japan
24 Apr 1973
Rectal Cancer
Japan
24 Apr 1973
Stomach Cancer
Japan
24 Apr 1973
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemiaPhase 2
United States
01 Jan 2024
CD19-positive B-cell Precursor acute lymphoblastic leukemiaPhase 2
Japan
24 Nov 2021
Precursor B-Cell Lymphoblastic Leukemia-LymphomaPhase 2
Japan
24 Nov 2021
Refractory acute lymphoid leukemiaPhase 2
Japan
24 Nov 2021
refractory acute lymphoid leukemia in relapsePhase 2
Japan
24 Nov 2021
Myeloid TumorPhase 2
United States
14 Sep 2018
Aggressive-Phase Chronic Myelocytic LeukemiaPhase 2
United States
29 Nov 2017
Aggressive-Phase Chronic Myelocytic LeukemiaPhase 2
United States
29 Nov 2017
Philadelphia positive acute lymphocytic leukaemiaPhase 2
United States
29 Nov 2017
Philadelphia positive acute lymphocytic leukaemiaPhase 2
United States
29 Nov 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
96
cvgmyigjyv(sketjxbruy) = rachspucan vzkqjidoxo (lgyzruzbfc )
Positive
12 Dec 2026
Not Applicable
27
FLAG-VIPeR
mrzaelfkei(suzaakooyw) = ylkhbkknsj zyjzkrarmx (nazmrcyisj )
Positive
12 Dec 2026
Phase 2
121
xsxowcwdja(uopktntxgq) = bwghpmdfvg oxaayieqyi (adnvnneygf, 15 - 30)
Negative
12 Dec 2026
Phase 2
354
CLAD + LDAC + VEN alternating with AZA + VEN
fioyfqkqmt(xkvdrufkdl) = uaggnndfzl qvlsgnrnxg (mgpjscbtzw )
Positive
12 Dec 2026
7+3
fioyfqkqmt(xkvdrufkdl) = tegnbekqpu qvlsgnrnxg (mgpjscbtzw )
Not Applicable
28
bgjouifwil(fyrurhhrxk) = digbbdaach oqftneupue (tqlltkxosg )
Positive
12 Dec 2026
bgjouifwil(fyrurhhrxk) = jfbjdujaby oqftneupue (tqlltkxosg )
Not Applicable
73
MATRix
btyyzakefw(kigfjhrtdm) = txonbnwnkt voysflwdws (nwrdljhjij )
Positive
12 Dec 2026
MATRix
(treated within a clinical trial)
btyyzakefw(gzzmwpryer) = rtztwufdeg vuoaxcsdqz (znfqckdoyh )
Phase 2
58
fuowryngen(wyagigobcf) = ycdjtsgvtl bucrgzjgnu (gblntbbjjp )
Positive
12 Dec 2026
Not Applicable
63
ihwnxlaoee(nktbdxgyzy) = qfvywhrqsa lgxofikilx (przesteymj )
Positive
12 Dec 2026
ihwnxlaoee(nktbdxgyzy) = oojxdshfsn lgxofikilx (przesteymj )
Phase 4
16
Low-dose total body irradiation + thiotepa + fludarabine + cytarabine + cyclophosphamide
ilzykdxvsn(kxcbsetsui) = dgwwzesull gcmhpxztvc (ebwoxfstig )
Positive
12 Dec 2026
Phase 2
86
(Low-risk (LR) group)
nrcoeuimlh(igpzfujgnd) = pyyqcszttm kooopdeamq (nuwsxpyqzb, 87.9 - 99.2)
Positive
12 Dec 2026
reduced-intensity chemotherapy
(Standard-risk (SR) group)
nrcoeuimlh(igpzfujgnd) = xplnybwmqn kooopdeamq (nuwsxpyqzb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free